IQ-AI Ltd
("IQ-AI" or the
"Company")
IB
awarded a $100,000 grant by the Musella Foundation
Imaging Biometrics, LLC (IB), a
wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces that it
has been awarded a $100,000 grant by the Musella Foundation For
Brain Tumor Research & Information, Inc. The grant will help
support the launch of the recently announced intermediate group
expanded access program (iEAP). The iEAP will allow brain tumor
patients access to oral (pill form) gallium maltolate (GaM) outside
of the on-going phase 1 clinical trial on-going at the Medical
College of Wisconsin (MCW).
The Musella Foundation provided an
initial award towards the on-going phase 1 clinical trial being
conducted at the Medical College of Wisconsin (MCW). Since then, IB
has maintained and fostered a close relationship with The Musella
Foundation.
"Our
interest in this particular agent is growing. It appears to be
extremely well tolerated and may possess clinical benefit for
patients who have exhausted standard therapies," said Dr. Al
Musella, Founder and President of The Musella
Foundation.
The grant will be used to facilitate
the iEAP including writing and submitting the study protocol,
patient screening and on-boarding, and more.
"This iEAP
will enable brain tumor patients with limited or no other treatment
alternatives to gain access to oral GaM. We appreciate the support
from the Musella Foundation and IQ-AI who helped make this happen,"
said Dr. Jennifer Connelly, MD, Professor of Neurology at MCW and
co-PI of the trial.
--ENDS-
The Directors of the Company accept
responsibility for the contents of this announcement.
For further information, please
contact:
|
IQ-AI Ltd
Trevor Brown/Vinod Kaushal/Brett
Skelly/Michael Schmainda
Tel: 020 7469 0930
|
|
Peterhouse Capital Limited (Financial Adviser and
Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
|
About The Musella
Foundation
The Musella Foundation For Brain Tumor Research &
Information, Inc is a 501(C)3 nonprofit public charity dedicated to
helping brain tumor patients through emotional and financial
support, education, advocacy and raising money for brain tumor
research. Visit virtualtrials.org for more information.
About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI),
and focuses on delivering quantitative imaging platforms and
therapeutics that transform how clinicians diagnose and treat
patients more efficiently and effectively. For more information
about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com. Follow
IB on Twitter, @IQAI_IB.
